Literature DB >> 19569978

Risk of venous thromboembolism due to antipsychotic drug therapy.

Staffan Hägg1, Anna K Jönsson, Olav Spigset.   

Abstract

An increasing number of reports suggest a link between venous thromboembolism (VTE) and the use of antipsychotics. To better understand this association the available body of evidence has been critically scrutinised. Relevant articles were identified in the databases Scopus and PubMed. Several observational studies using different methodologies show an increased risk of VTE in psychiatric patients. This elevated risk seems to be related to the use of antipsychotic medication and in particular to the use of clozapine and low-potency first-generation drugs. Many studies investigating the association have, however, methodological limitations. The biological mechanisms involved in the pathogenesis of this possible adverse reaction are largely unknown but several hypotheses have been suggested such as drug-induced sedation, obesity, increased levels of antiphospholipid antibodies, enhanced platelet aggregation, hyperhomocysteinemia and hyperprolactinemia. The association may also be related to underlying risk factors present in psychotic patients. Physicians need to be aware of this possible adverse drug reaction. Although supporting evidence has not been published they should consider discontinuing or switching the antipsychotic treatment in patients experiencing VTE. In addition, although data is lacking, the threshold for considering prophylactic antithrombotic treatment should be low when risk situations for VTE arise, such as immobilisation, surgery and so on.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19569978     DOI: 10.1517/14740330903117271

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  18 in total

Review 1.  Anticoagulation and psychotropic medications.

Authors:  Maurice Bachawati
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

2.  Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies.

Authors:  Corrado Barbui; Valentino Conti; Andrea Cipriani
Journal:  Drug Saf       Date:  2014-02       Impact factor: 5.606

Review 3.  Morbidity and mortality associated with the utilization of restraints : a review of literature.

Authors:  Maryam Rakhmatullina; Abraham Taub; Theresa Jacob
Journal:  Psychiatr Q       Date:  2013-12

Review 4.  Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management.

Authors:  Anna K Jönsson; Olav Spigset; Staffan Hägg
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

5.  Review of thromboembolic prophylaxis in patients attending Cork University Hospital.

Authors:  Stephen Byrne; Daniel Timothy Weaver
Journal:  Int J Clin Pharm       Date:  2013-03-15

6.  Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study.

Authors:  Jiří Masopust; Radovan Malý; Ctirad Andrýs; Martin Vališ; Jan Bažant; Ladislav Hosák
Journal:  BMC Psychiatry       Date:  2011-01-03       Impact factor: 3.630

7.  Venous thromboembolism prophylaxis in mental healthcare: do the benefits outweigh the risks?

Authors:  Rashmi Patel
Journal:  BJPsych Bull       Date:  2015-04

Review 8.  Rare and very rare adverse effects of clozapine.

Authors:  Pasquale De Fazio; Raffaele Gaetano; Mariarita Caroleo; Gregorio Cerminara; Francesca Maida; Antonio Bruno; Maria Rosaria Muscatello; Maria Jose Jaén Moreno; Emilio Russo; Cristina Segura-García
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-06       Impact factor: 2.570

9.  Venous thromboembolism following initiation of atypical antipsychotics in two geriatric patients.

Authors:  Thomas J Maestri; Jessica Koenig; Christine Masuda; Tawny L Smith; Erica C Garcia-Pittman
Journal:  Ment Health Clin       Date:  2018-03-23

10.  Pulmonary embolism related to amisulpride treatment: a case report.

Authors:  Maria Skokou; Philippos Gourzis
Journal:  Case Rep Psychiatry       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.